Hernández Rosales Frank A, Calunga Fernández José L, Turrent Figueras José, Menéndez Cepero Silvia, Montenegro Perdomo Adonis
Departmento de Biomedicina, Centro de Investigaciones del Ozono del Centro Nacional de Investigaciones Científicas, Ciudad de la Habana, Cuba.
Arch Med Res. 2005 Sep-Oct;36(5):549-54. doi: 10.1016/j.arcmed.2005.04.021.
The relationship and behavior of serum immunoglobulin E (IgE) level, peripheral blood mononuclear cell (PBMC) human leukocyte antigen DR (HLA-DR) expression and erythrocyte glutathione antioxidant pathway in asthma patients treated with systemic ozone therapy have not been studied before.
Asthma patients were treated about 1 year with three cycles (5 or 6 months each) with three different ozone therapy protocols. Ozone major autohemotherapy (MAHT) was applied at doses of 4 and 8 mg, 15 sessions each cycle; and ozone rectal insufflations (RI) at a dose of 10 mg, 20 sessions each cycle. Serum IgE, HLA-DR expression in PBMC and biomarkers for antioxidant pathway were measured before and at the end of each cycle. Lung function and symptoms test were recorded at the beginning and after the third cycle.
IgE and HLA-DR decreased with the three types of treatments, while increments in reduced glutathione, glutathione peroxidase, glutation reductase and glutathione S-transferase were achieved with all treatments. Lung function and symptoms test were markedly improved. However, in all parameters the best response was obtained in the order: MAHT at 8 mg better than MAHT at 4 mg better than RI at 10 mg. Before ozone treatment, glutathione antioxidant parameters were under the normal reference values, suggesting the occurrence of oxidative stress associated with atopic asthma.
This study demonstrates the effectiveness of ozone therapy in reducing IgE and inflammatory mediators along with the induction of antioxidant elements. The study raises the role of systemic ozone therapy in atopic asthma by means of its immunomodulatory and oxidative stress regulation properties.
系统性臭氧疗法治疗哮喘患者时,血清免疫球蛋白E(IgE)水平、外周血单个核细胞(PBMC)人类白细胞抗原DR(HLA-DR)表达与红细胞谷胱甘肽抗氧化途径之间的关系及行为此前尚未被研究。
哮喘患者接受约1年的治疗,分三个周期(每个周期5或6个月),采用三种不同的臭氧疗法方案。臭氧大自血疗法(MAHT)以4毫克和8毫克的剂量应用,每个周期15次;臭氧直肠注入(RI)以10毫克的剂量应用,每个周期20次。在每个周期开始前和结束时测量血清IgE、PBMC中HLA-DR的表达以及抗氧化途径的生物标志物。在第三个周期开始时和结束后记录肺功能和症状测试结果。
三种治疗方式均使IgE和HLA-DR降低,同时所有治疗方式均使还原型谷胱甘肽、谷胱甘肽过氧化物酶、谷胱甘肽还原酶和谷胱甘肽S-转移酶增加。肺功能和症状测试有明显改善。然而,在所有参数中,最佳反应顺序为:8毫克的MAHT优于4毫克的MAHT优于10毫克的RI。在臭氧治疗前,谷胱甘肽抗氧化参数低于正常参考值,提示与特应性哮喘相关的氧化应激的发生。
本研究证明了臭氧疗法在降低IgE和炎症介质以及诱导抗氧化元素方面的有效性。该研究通过其免疫调节和氧化应激调节特性提高了系统性臭氧疗法在特应性哮喘中的作用。